[Does quinapril improve coronary vasoconstriction in vasospastic angina?]

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Endothelial dysfunction is a key factor in coronary spasm.
• Angiotensin-converting enzyme (ACE) inhibitors like quinapril have shown potential in improving endothelial function.
• Vasospastic angina involves coronary vasoconstriction, often linked to endothelial dysfunction.

Purpose of the Study:

• To investigate the efficacy of quinapril in improving acetylcholine-induced coronary vasoconstriction in patients with vasospastic angina.
• To assess the impact of quinapril on coronary spasm parameters in patients with vasospastic angina.

Main Methods:

• A randomized controlled trial involving 24 patients diagnosed with vasospastic angina via acetylcholine provocation test.
• Patients were assigned to either a quinapril group (20 mg/day) or a non-quinapril group, with all patients receiving calcium antagonists.
• Coronary angiography was repeated after six months to compare changes in coronary spasm between the groups (17 patients evaluated).

Main Results:

• Angina symptoms were largely suppressed in all patients during the study.
• No significant differences in the improvement, deterioration, or stability of coronary spasm were observed between the quinapril and non-quinapril groups.
• Quantitative angiographic analysis revealed no significant interval changes in the coronary spasm rate between the two groups (p = 0.60).

Conclusions:

• Quinapril did not demonstrate a significant improvement in coronary vasoconstriction induced by acetylcholine in patients with vasospastic angina.
• The study suggests that quinapril may not be an effective treatment for improving endothelial dysfunction-related coronary vasoconstriction in this patient population.